loader2
Partner With Us NRI

Supriya Lifescience Ltd share Price Today

Company details

395.00
403.20
233.30
424.00
6M Return 44.52%
1Y Return 58.98%
Mkt Cap.(Cr) 3,217.31
Volume 80,416
Div Yield 0.20%
OI
-
OI Chg %
-
Volume 80,416

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Supriya Lifescience announced Q1FY24 results:

  • Total revenue of Rs 134.9 crore in Q1FY24, as compared to Rs 103.7 crore in Q1FY23
  • Total PAT of Rs 28.51 crore in Q1FY24, as compared to Rs 25.25 crore in Q1FY23
  • Reported PAT margin of 22%
  • Reported Gross profit of 64%
  • EBITDA reported Rs 44.49 crore in Q1FY24, as compared to Rs 31.25 crore in Q1FY23
  • Healthy EBITDA margin of 34% reported in Q1FY24
  • Asian market contributed over 40% of the business, whereas Europe contributed 35%

Satish Wagh, Chairman and Managing Director, Supriya Lifescience, commenting on their results said, “The company has been resilient to the global economic conditions and has delivered a strong comeback. Our strategic business initiatives of deeper penetration in existing markets and tapping new markets, backed by our world-class R&D capabilities, have been the key growth drivers for our business. The demand from regulated markets like Europe, North America, and Latin America have surged and come back to normalcy.”

 

 

 

Result PDF

View Other Company Results

Supriya Lifescience Ltd shares SWOT Analysis

Strengths (8)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Growth in Net Profit with increasing Profit Margin (QoQ)
  • Company with No Debt

Weakness (1)

  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (0)

Data not found

Resistance and support

R1 407.4
R2 415.8
R3 421.6
Pivot

401.62

S1 393.2
S2 387.4
S3 379.0
EMA SMA
379.7
372.7
357.2
331.3
370.4
379.2
360.4
318.9
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-02-08 342.21 627793 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2024-02-08 342.32 627793 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2023-12-26 312.26 456665 NSE
Name Category Shares
Satish Waman Wagh PROMOTER 67.64%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Supriya Lifescience Ltd Stocks COMPARISON

Financials( in Cr) Supriya Lifescience Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 399.75 1,498.75 1,519.30 4,550.00 1,087.90
% Change 0.18 2.15 -1.44 0.62 0.26
Mcap Cr 3,217.31 359,600.33 122,663.27 120,788.40 109,468.20
Revenue TTM Cr 460.94 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 89.86 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 26.84 35.16 29.22 74.99 28.33
1 Year Return 58.98 51.10 50.59 29.65 94.23
ROCE 18.43 16.79 14.76 19.30 16.25
ROE 13.67 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 699.46 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,841.27 9,567.52
LAST 3M 107,380.98 -15,756.42
LAST 6M 182,851.12 -2,333.61
LAST 12M 296,057.08 99,791.83

Supriya Lifescience Ltd Information

Stock PE (TTM)
26.84
Promoter Holding
68.3%
Book Value
101.3094
ROCE
18.43%
ROE
13.67%
Description
  • The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company`s products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company`s business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. The new clean rooms will add manufacturing capacity of 215 KL per day. On 31 March 2012,the company has issued and allotted 3002400 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 12:1. On 31 March 2013,the company has issued and allotted 1626302 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 1:2. On 01 October 2015,the company has issued and allotted 9757804 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 2:1 On 26 December 2020,the company has sub-divided its face value of equity shares from Rs 10 each to Rs 2 each. During the month of December 2021,the company came out with an Rs 700-crore public issue which comprised of a fresh issue of Rs 200 crore and an offer for sale(OFS) of Rs 500 crore by the promoter Satish Waman Wagh.The IPO shares were allotted at the price of Rs 274 per share including a premium of Rs 272 per share.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India Ltd(NSE) on 28 December 2021.

Registered Address

207/208 Udyog Bhavan, Sonawala Road Goregaon (East), Mumbai, Maharashtra, 400063

Tel : 91-22-40332727
Email : cs:supriyalifescience.com
Website : http://www.supriyalifescience.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543434
NSE Code : SUPRIYA
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE07RO01027

FAQ’s on Supriya Lifescience Ltd Shares

You can buy Supriya Lifescience Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Supriya Lifescience Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 24, 2024 12:04 PM the closing price of Supriya Lifescience Ltd was Rs.399.75.

The latest PE ratio of Supriya Lifescience Ltd as of Jun 24, 2024 12:04 PM is 26.84

The latest PB ratio of Supriya Lifescience Ltd as of Jun 24, 2024 12:04 PM is 0.25

The 52-week high of Supriya Lifescience Ltd share price is Rs. 424.00 while the 52-week low is Rs. 233.30

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 24, 2024 12:04 PM, the market cap of Supriya Lifescience Ltd stood at Rs. 3,217.31 Cr.

Download App

Download Our App

Play Store App Store
market app